(Q45259654)

English

Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse

scientific article published in April 2005

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

author name string

Marin D

1

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Kaeda J

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Saunders S

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Fleming A

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Howard J

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Andreasson C

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Bua M

8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Olavarria E

9

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Rahemtulla A

10

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Dazzi F

11

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Kanfer E

12

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Goldman JM

13

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Apperley JF

14

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 April 2005

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

507-512

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Characteristics of accelerated disease in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Lymphoid transformation in a CML patient in complete cytogenetic remission following treatment with imatinib

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403664

21 January 2018

Identifiers

10.1038/SJ.LEU.2403664

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45259654&oldid=2207178182"